In this lecture, you will learn about the latest initiatives in digital drug discovery from the perspectives of the roles of the ecosystem, including digital drug discovery research, application development, computational resource infrastructure provision, and industrialization, as a consortium.
Chiral Inc. will introduce examples, including new services that meet the needs of researchers from various backgrounds.
Through the Chiral SaaS Ember platform, Chiral Inc. has already been providing drug discovery applications such as myPresto5™. In this lecture and discussion, we will introduce two new products, Potter and Silva, in addition to Chiral SaaS.
Potter is a product aimed at a broader user base, enabling the creation of workflows across multiple applications without coding.
Silva is a tool developed for users already familiar with terminal tools. It allows users to leverage existing scripts and extend processes such as computational resource allocation.
In the discussion, not only drug discovery researchers but also drug discovery application development researchers will be invited to gain an overview of the history, challenges, and future development of digital drug discovery.
During the discussion, participants will be able to post questions through an online system, and the speakers will provide answers. We look forward to your active participation.
To participate in this lecture and discussion, please register via the provided link. Peatix Link
The Japan Bioindustry Consortium (JBIC) conducts research and development of fundamental technologies in the health and medical fields through industry-academia-government collaboration and disseminates the results widely to industries such as pharmaceuticals and IT, as well as academia. JBIC promotes cutting-edge research and development, from foundational research to practical applications, to create innovative pharmaceuticals, medical devices, and utilize ICT in the health and medical fields. It also supports the smooth transition of these results to the industry. To strengthen Japan's drug discovery infrastructure and improve the efficiency of drug discovery research, JBIC conducts surveys and planning activities based on the needs of its member companies, focusing on the latest technological trends and new industry-academia-government collaboration initiatives and projects domestically and internationally.
myPresto5™ is an open-source molecular computation software for drug discovery support, developed by the Japan Bioindustry Consortium (JBIC) with support from the Japan Agency for Medical Research and Development (AMED), JBIC membership fees, and voluntary activities of developers. For more details, please visit https://www.mypresto5.jp/.
Chiral Inc. provides backend functionality as SaaS to enable cloud computing for software in fields such as life sciences and drug discovery, which require extensive computational processing.
Address：2-6-11 Daimyo, Chuo-ku, Fukuoka City, Fukuoka Prefecture, Fukuoka Growth Next
CEO：Qin Wang
Established：May 2021
Website：https://www.chiral.one
Chiral Inc.
Public Relations: Koji Umeda
TEL: 050-5539-4886
E-Mail: info@chiral.one
